BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Nov. 19, 2007
View Archived Issues
Human fibroblast growth factor safe, active in coronary artery disease patients
Read More
Prolonged renal effects seen with AlbuBNP in dogs
Read More
Sitaxsentan assessed as a possible treatment for Eisenmenger's syndrome
Read More
Combination therapy with lapaquistat and atorvastatin improves hypercholesterolemia
Read More
Bioponic launches Curemisinin for the treatment of malaria in Africa
Read More
Preclinical profile of Merck & Co.'s novel NR2B-selective NMDA antagonist
Read More
Neuroprotection by small-molecule Hedgehog agonist in an in vitro model of ischemia
Read More
Provectus begins phase II clinical trial for psoriasis
Read More
VaxGen and Raven announce definitive merger agreement
Read More
Novel antiatherosclerotic agents emerge from Merck & Co. R&D
Read More
Final positive results announced from phase II GHRH trial
Read More
New data for mipomersen in routine high cholesterol patients
Read More
MedImmune and Infinity initiate phase II clinical trial of IPI-504 for prostate cancer
Read More
Novexel initiates phase II clinical trial of NXL-103 for community-acquired pneumonia
Read More
Karo Bio initiates phase IIb clinical study of KB-2115 for dyslipidemia
Read More
Avax initiates phase III clinical study of M-Vax in metastatic melanoma
Read More
AEterna Zentaris completes patient enrollment in phase II trial of perifosine
Read More
Northwestern University initiates enrollment in phase IIb study of Nexavar
Read More
New agents for treating neurological disorders disclosed in recent patent literature
Read More
Ceregene completes enrollment in phase II clinical trial of CERE-120 for Parkinson's disease
Read More
Amylin reports positive results from phase IIa study of pramlintide and metreleptin
Read More
The Juvenile Diabetes Research Foundation and Lilly fund research in diabetes biomarkers
Read More
CHMP gives positive approval for Avastin for the first-line treatment of renal cell carcinoma
Read More
Pfizer acquires Coley Pharmaceutical Group
Read More
CHMP gives positive opinion for Abbott's Humira in treatment of moderate to severe plaque psoriasis
Read More
FDA approves Seroquel XR for maintenance treatment of schizophrenia
Read More
Tibotec initiates phase II trial of telaprevir in treatment-naive chronic hepatitis C patients
Read More
Novel small-molecule compound appears to extend L-DOPA antiparkinsonian effects
Read More